Tandem Diabetes Care, Inc.’s TNDM impressive international expansion is expected to bolster growth in the upcoming quarters. A robust diabetes market provides a favorable opportunity for the company’s ...

The Global Insulin Pump Market achieved a valuation of $5.90 Billion in 2024 and is anticipated to exceed $14.49 Billion by 2035, reflecting a compounded annual growth rate (CAGR) of 8.55% during the ...

It's a great strategy, but it's essential to avoid those companies that only look undervalued but actually aren't. Some stocks are lagging the market for good reasons -- because their businesses look ...

DXCM secures FDA clearance for its G7 15-Day CGM, the longest-lasting and most accurate wearable, enhancing user convenience and expanding diabetes care access.

Tandem's flagship product, the t:slim X2™ insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring. Tandem is based in ...

The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the ...

The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is ...

The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the ...